CEBPZ and acute myeloid leukemia: As with the earlier analysis of the pooled RRs of CBF-AML, we also separately pooled the RRs for 2- and 5-year relapse risks, which were 1.76 (95%CI: 1.45–2.12; P = 0.52, I2 = 0%) and 1.70 (95% CI: 1.31–2.21; P = 0.78, I2 = 0%), respectively.